Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Z1OR
|
|||
| Former ID |
DIB007262
|
|||
| Drug Name |
IPP-204106
|
|||
| Synonyms |
NucAnt 6L; N-6-L; Nucleolin antagonist (cancer), ImmuPharma; Nucleolin antagonist (cancer), ImmuPharma/CNRS; Nucleolin antagonist (cancer), ImmuPharma/Centre National de la Recherche Scientifique
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1/2 | [1] | |
| Company |
Centre National de la Recherche Scientifique (CNRS)
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nucleolin (NCL) | Target Info | Modulator | [2] |
| Nucleophosmin (NPM1) | Target Info | Modulator | [2] | |
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Pathway Interaction Database | Aurora B signaling | |||
| Validated targets of C-MYC transcriptional activation | ||||
| HIF-1-alpha transcription factor network | ||||
| BARD1 signaling events | ||||
| Regulation of Telomerase | ||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| WikiPathways | Host Interactions of HIV factors | |||
| Nucleosome assembly | ||||
| Pathogenic Escherichia coli infection | ||||
| miR-targeted genes in squamous cell - TarBase | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01711398) Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IPP-204106N on Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Company report (ImmuPharma) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.